Ronald DePinho from MD Anderson to Present in Translational Biotechnology Seminar Series



Targeting the Tumor Microenvironment

Ronald A. DePinho, M.D.

Past President
Distinguished University Professor
MD Anderson Cancer Center

Wednesday, October 5, 2022
1:00 - 2:00 pm Webinar Registration
2:00 - 3:00 pm Conversation with trainees

Ronald A. DePinho, M.D. is the past president and distinguished university professor at MD Anderson Cancer Center in Houston, Texas. He studied biology at Fordham University, where he graduated salutatorian, received his M.D. degree with distinction from the Albert Einstein College of Medicine, and performed his residency and postdoctoral training at Columbia-Presbyterian Medical Center. His research career began at Einstein as the Feinberg Senior Faculty Scholar in Cancer Research and an ACS Research Professor. He then joined the Dana-Farber Cancer Institute and Harvard Medical School where he was the founding Director of the Belfer Institute for Applied Cancer Science. During his 6-year tenure as MD Anderson’s president, Dr. DePinho conceived and launched the Cancer Moon Shots Program, enhanced MD Anderson’s research and training excellence, recruited many world class faculty including its first Nobel, and expanded its global network to reach one-third of the human population. His research program has made fundamental contributions to our understanding of cancer, aging and degenerative disorders, and these discoveries have led to clinical advances. For his contributions to cancer, aging and healthcare, Dr. DePinho has been received the AACR Clowes Memorial Award, the Albert Szent-Gyorgyi Prize, the Ellis Island Medal of Honor, Portugal’s Order of Saint James of the Sword, among other awards and honors. He is a member of the National Academy of Medicine and the National Academy of Science, and a fellow of the American Academy of Arts and Sciences, the American Association of the Advancement of Science and the American Association of Cancer Research.

  seminar flyer and contact information

Department Chair John Carpten to Chair President Biden’s National Cancer Advisory Board

President Joe Biden has appointed Dr. Carpten to serve as chair of the administration’s National Cancer Advisory Board, which plays an important role in guiding the director of the National Cancer Institute in setting the course for the national cancer research program. 


White House Press Release

USC News

Translational Genomics Concluded Genomic Diversity and Human Disease Lecture Series

We wish to thank all our speakers for bringing their expertise and engaging in candid discussions with students throughout the semester.  Please see full list of lectures here. 

Department Chair Dr. Carpten Kicked Off Translational Genomics Virtual Distinguished Lecture Series


USC Translational Genomics:
Accelerating Improvements in Healthcare at USC KSOM through Intentional Integration between Basic Discovery Research and Clinical Science

John D. Carpten, PhD
Professor, USC Department of Urology
Chair, USC Department of Translational Genomics
Director, USC Institute for Translational Genomics
Director, USC Molecular Genomics Core
Co-Leader, Norris Comprehensive Cancer Center

Tuesday, August 18, 2020
11:00 am – 12:00 pm

In 2016, the USC Department of Translational Genomics was created under the leadership of the founding chair John Carpten, PhD with co-leadership by Vice Chair Dr. David Craig.  The mission of USC Translational Genomics is to help the Keck School of Medicine realize its full potential in improving patient outcomes through the intentional integration of basic and clinical research.  The foundational components of our department include genome science and biomedical informatics.  The department currently includes eight faculty members dedicated to scholarship, teaching and education, and service to the community.  The department hosts several major grants and is focused on translating genomic discoveries into new knowledge that may someday have clinical application.  The department also contributes to the educational mission of the university through its master’s degree programs in Translational Biotechnology and Translational Biomedical Informatics.   Diversity is also a major component of our departmental foundation, including being among the world leaders in research studies that aim to understand the relationship between population differences and disease incidence and outcomes, and in our intentional goals for biomedical workforce diversity.

  seminar flyer and contact information
  presentation slides:      Deck 1           Deck 2